A Study of SC10914 in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
SC10914 is a potent selective PARP-1 and PARP-2 inhibitor. This study aims to determine the
safety , tolerability , pharmacokinetic/pharmacodynamics profile of increasing doses of
SC10914 when administered orally to patients with advanced solid tumors. Furthermore, the
safety and efficacy of SC10914 in patients with advanced solid tumors and negative expression
of ATM or BRCA1 or BRCA2 mutation will be evaluated in expanded cohorts to establish the
Recommended Phase 2 Dose(RP2D).